We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
NeuroPace's RNS adoption, reimbursement and referral expansion support growth despite profit pressure.
AI tools and 27M intracranial EEG recordings strengthen NeuroPace's data-driven platform.
IGE expansion could broaden NeuroPace's market, but FDA data requests may delay approval and launch.
NeuroPace, Inc. (NPCE - Free Report) is well-positioned for solid growth, driven by strong RNS adoption, favorable RNS reimbursement, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indication offers a long-term growth opportunity. However, near-term profitability may be pressured by higher investments and seasonality, while IGE contribution could be delayed due to approval uncertainty, payer coverage expansion and physician adoption, leaving the core business to drive growth.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have lost 4.5% compared with the industry’s 8% decline. However, the S&P 500 has risen 10% in the same timeframe.
As a developer of neuromodulation technology for epilepsy, NeuroPace’s core product is the RNS System, a closed-loop, brain-responsive implant that monitors intracranial EEG, detects patient-specific abnormal electrical patterns and delivers targeted stimulation to help prevent seizures. It has a market capitalization of $521.4 million.
The company projects 59.5% growth for 2027 and expects to maintain its strong performance going forward. NeuroPace’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 31.2%.
Image Source: Zacks Investment Research
Factors Favoring NPCE’s Growth
Favorable Reimbursement and Prescriber Expansion: NeuroPace benefits from established reimbursement for RNS implantation, programming and monitoring, with Medicare reimbursement enhancements effective Jan. 1, 2026, and positive commercial coverage policies spanning more than 200 million lives. The company also reached record highs in active prescribers, accounts and patient pipeline in the second quarter of 2026, while expanding beyond Level 4 epilepsy centers into community neurologists and Level 3 programs. This broader referral network can improve patient identification and support sustained RNS utilization.
AI and Data-Driven Differentiation: NeuroPace launched ECoG Assistant in the second quarter of 2026 as the first product in its planned AI suite, helping clinicians identify relevant ECoGs, assess trends and evaluate circadian patterns. With more than 27 million proprietary intracranial EEG recordings, the company has a differentiated data asset supporting future AI development. Its pipeline also includes multimodal foundational models, automated detection, remote care capabilities and a next-generation RNS system, expanding the platform beyond implantable hardware.
Potential IGE Expansion: The FDA's July 2026 response delayed the IGE expansion, requesting additional information concerning clinical benefit across patient subgroups and the clinical relevance of reducing generalized tonic-clonic seizures, rather than raising safety concerns. NeuroPace plans to submit further analyses, patient and physician-reported outcomes, real-world evidence and 24-month NAUTILUS data. Approval could significantly expand the company’s addressable market beyond focal epilepsy while leveraging its existing RNS technology and commercial infrastructure.
Factors That May Offset the Gains for NPCE
Profitability Pressures: NeuroPace continues to operate at a loss as it invests in commercial expansion, AI-enabled tools, regulatory programs and its next-generation platform. Although management improved full-year 2026 adjusted EBITDA guidance to a loss of $7.5 million to $8.5 million, continued spending on sales infrastructure, product development and broader patient access could keep cash generation constrained in the near term. The investment case therefore depends on these initiatives translating into higher RNS adoption and greater operating leverage over time. Slower conversion of the patient pipeline or delays in product and regulatory milestones could extend the path to cash flow breakeven.
Regulatory Uncertainty Around IGE Expansion: NeuroPace’s planned expansion into drug-resistant IGE remains subject to regulatory uncertainty. The FDA recently determined that the company’s PMA supplement was not approvable in its current form. Although management remains confident in a path toward approval, further data requests or a potential reset of the FDA’s 180-day review clock could delay the launch and limit the near-term growth opportunity.
Execution Risks as Expansion Accelerates: NPCE’s long-term plans of sustaining more than 20% growth will require it to increase physician adoption and utilization within Level 4 epilepsy centers while expanding into Level 3 and community settings. Patient journeys for focal epilepsy can take six months to a year, creating potential delays in converting the existing pipeline into implants. At the same time, investments in AI, remote care and the next-generation RNS platform require successful development, regulatory approval and adoption to translate into meaningful commercial benefits.
NeuroPace has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its loss has narrowed by 4 cents to 37 cents per share.
The Zacks Consensus Estimate for 2026 revenues is pegged at $100.3 million, indicating a 0.3% increase from the year-ago reported numbers.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
Key Takeaways
NeuroPace, Inc. (NPCE - Free Report) is well-positioned for solid growth, driven by strong RNS adoption, favorable RNS reimbursement, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indication offers a long-term growth opportunity. However, near-term profitability may be pressured by higher investments and seasonality, while IGE contribution could be delayed due to approval uncertainty, payer coverage expansion and physician adoption, leaving the core business to drive growth.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have lost 4.5% compared with the industry’s 8% decline. However, the S&P 500 has risen 10% in the same timeframe.
As a developer of neuromodulation technology for epilepsy, NeuroPace’s core product is the RNS System, a closed-loop, brain-responsive implant that monitors intracranial EEG, detects patient-specific abnormal electrical patterns and delivers targeted stimulation to help prevent seizures. It has a market capitalization of $521.4 million.
The company projects 59.5% growth for 2027 and expects to maintain its strong performance going forward. NeuroPace’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 31.2%.
Image Source: Zacks Investment Research
Factors Favoring NPCE’s Growth
Favorable Reimbursement and Prescriber Expansion: NeuroPace benefits from established reimbursement for RNS implantation, programming and monitoring, with Medicare reimbursement enhancements effective Jan. 1, 2026, and positive commercial coverage policies spanning more than 200 million lives. The company also reached record highs in active prescribers, accounts and patient pipeline in the second quarter of 2026, while expanding beyond Level 4 epilepsy centers into community neurologists and Level 3 programs. This broader referral network can improve patient identification and support sustained RNS utilization.
AI and Data-Driven Differentiation: NeuroPace launched ECoG Assistant in the second quarter of 2026 as the first product in its planned AI suite, helping clinicians identify relevant ECoGs, assess trends and evaluate circadian patterns. With more than 27 million proprietary intracranial EEG recordings, the company has a differentiated data asset supporting future AI development. Its pipeline also includes multimodal foundational models, automated detection, remote care capabilities and a next-generation RNS system, expanding the platform beyond implantable hardware.
Potential IGE Expansion: The FDA's July 2026 response delayed the IGE expansion, requesting additional information concerning clinical benefit across patient subgroups and the clinical relevance of reducing generalized tonic-clonic seizures, rather than raising safety concerns. NeuroPace plans to submit further analyses, patient and physician-reported outcomes, real-world evidence and 24-month NAUTILUS data. Approval could significantly expand the company’s addressable market beyond focal epilepsy while leveraging its existing RNS technology and commercial infrastructure.
Factors That May Offset the Gains for NPCE
Profitability Pressures: NeuroPace continues to operate at a loss as it invests in commercial expansion, AI-enabled tools, regulatory programs and its next-generation platform. Although management improved full-year 2026 adjusted EBITDA guidance to a loss of $7.5 million to $8.5 million, continued spending on sales infrastructure, product development and broader patient access could keep cash generation constrained in the near term. The investment case therefore depends on these initiatives translating into higher RNS adoption and greater operating leverage over time. Slower conversion of the patient pipeline or delays in product and regulatory milestones could extend the path to cash flow breakeven.
Regulatory Uncertainty Around IGE Expansion: NeuroPace’s planned expansion into drug-resistant IGE remains subject to regulatory uncertainty. The FDA recently determined that the company’s PMA supplement was not approvable in its current form. Although management remains confident in a path toward approval, further data requests or a potential reset of the FDA’s 180-day review clock could delay the launch and limit the near-term growth opportunity.
Execution Risks as Expansion Accelerates: NPCE’s long-term plans of sustaining more than 20% growth will require it to increase physician adoption and utilization within Level 4 epilepsy centers while expanding into Level 3 and community settings. Patient journeys for focal epilepsy can take six months to a year, creating potential delays in converting the existing pipeline into implants. At the same time, investments in AI, remote care and the next-generation RNS platform require successful development, regulatory approval and adoption to translate into meaningful commercial benefits.
NeuroPace, Inc. Price
NeuroPace, Inc. price | NeuroPace, Inc. Quote
Estimate Trend
NeuroPace has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its loss has narrowed by 4 cents to 37 cents per share.
The Zacks Consensus Estimate for 2026 revenues is pegged at $100.3 million, indicating a 0.3% increase from the year-ago reported numbers.
Key Picks
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.